Carlos R. Camara-Lemarroy

Monterrey, NLE, Mexico

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 117 publications

Serum angiogenesis-hypoxia biomarkers in relapsing-remitting multiple sclerosis.

Serum angiogenesis-hypoxia biomarkers in relapsing-remitting multiple sclerosis.

Journal: Multiple sclerosis and related disorders

Published: April 25, 2026

Taking progressive biology seriously in the time of B-cells and BTK.

Taking progressive biology seriously in the time of B-cells and BTK.

Journal: Multiple sclerosis and related disorders

Published: February 26, 2026

Angiogenesis and Hypoxia Biomarkers Are Dysregulated in Progressive Multiple Sclerosis.

Angiogenesis and Hypoxia Biomarkers Are Dysregulated in Progressive Multiple Sclerosis.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: September 18, 2025

Progression independent of relapsing biology in multiple sclerosis: a real-word study.

Progression independent of relapsing biology in multiple sclerosis: a real-word study.

Journal: Frontiers in neurology

Published: March 18, 2025

Very Delayed SMART Syndrome.

Very Delayed SMART Syndrome.

Journal: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques

Published: February 24, 2025

Brainstem and Central Variant PRES in Hypertensive Encephalopathy.

Brainstem and Central Variant PRES in Hypertensive Encephalopathy.

Journal: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques

Published: February 06, 2025

Multiple Sclerosis and biological definitions in neurodegenerative diseases.

Multiple Sclerosis and biological definitions in neurodegenerative diseases.

Journal: Multiple sclerosis and related disorders

Published: November 07, 2024

Selecting Informative Patients for Phase 2 Progressive Trials in MS: Design Considerations for Phase 2 Clinical Trials in Progressive MS.

Selecting Informative Patients for Phase 2 Progressive Trials in MS: Design Considerations for Phase 2 Clinical Trials in Progressive MS.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: September 09, 2024

Elucidating the Significance of Zonulin in the Pathogenesis of Chronic Inflammatory Disorders: Emphasis on Intestinal Barrier Function and Tight Junction Regulation.

Elucidating the Significance of Zonulin in the Pathogenesis of Chronic Inflammatory Disorders: Emphasis on Intestinal Barrier Function and Tight Junction Regulation.

Journal: Current medicinal chemistry

Published: June 06, 2024

Soluble adhesion molecules: Cognitive worsening biomarkers in primary progressive multiple sclerosis?

Soluble adhesion molecules: Cognitive worsening biomarkers in primary progressive multiple sclerosis?

Journal: Journal of neuroimmunology

Published: February 14, 2024

Biomarkers of disability worsening in inactive primary progressive multiple sclerosis.

Biomarkers of disability worsening in inactive primary progressive multiple sclerosis.

Journal: Journal of neuroimmunology

Published: September 25, 2023

Prolonged Transient Global Amnesia: Part of the Clinical Spectrum or a Separate Disease Entity?

Prolonged Transient Global Amnesia: Part of the Clinical Spectrum or a Separate Disease Entity?

Journal: The Neurohospitalist

Published: September 13, 2023

Showing 1-12 of 117

Last Updated: 09/26/2026